Rapid Plant based Antibody Production Service

Creative Biolabs provides a rapid plant-based antibody production service that solves issues in long antibody development timelines, difficulties in achieving high-yield antibody production, and the need for cost-effective manufacturing, thereby accelerating your research and development, obtaining high-quality antibodies, and streamlining your production process.

The Advantages of Plant-based Antibody Production

Leveraging plants as bioreactors, plant-based antibody generation has become a viable substitute for conventional mammalian cell culture methods. Among numerous benefits this method provides are scalability, economy, and less chance of mammalian pathogen infection. Extensive research has helped to promote the development of plant-based antibody manufacture by proving its ability to generate a range of antibodies for both therapeutic and diagnostic uses.

Fig.1 The utilization of plant-based expression systems in response to SARS-CoV-2 virus pandemicsfig.^1,3

Rapid Plant based Antibody Production Service at Creative Biolabs

Creative Biolabs offers a rapid plant-based antibody production service utilizing Nicotiana benthamiana for transient expression, allowing for the initiation of protein expression in under three weeks from antibody sequence identification. This system provides a cost-effective alternative to traditional mammalian cell-based production by eliminating the need for complex bioreactors and reducing the risk of mammalian pathogen contamination. our plant expression platform is capable of producing a broad range of antibody formats, including full-size antibodies and various functional derivatives, offering a flexible and scalable solution for rapid antibody production. Throughout the whole process, we adhere to rigorous standards and employ advanced techniques to guarantee the integrity, purity, and functionality of the final antibody product. This commitment to quality ensures that our clients receive reliable and consistent results, thereby empowering their research and development endeavors.

Our Workflow

The genetic sequence corresponding to the target antibody is inserted into a plant-compatible expression vector, which is subsequently transfected into Agrobacterium tumefaciens strains.

Recombinant Agrobacterium strains harboring the antibody expression construct are cultivated under optimal growth conditions to achieve cell densities suitable for plant transformation.

A suspension of the engineered Agrobacterium is introduced into Nicotiana benthamiana specimens, either at the seedling or mature growth stage, using vacuum infiltration. This technique facilitates transient gene transfer into plant cell nuclei.

Post-infiltration, plants are maintained in controlled environmental chambers for 3-7 days to enable transient expression of the recombinant antibody within plant tissues.

Following the incubation period, leaf tissue is homogenized, and total soluble proteins—including the synthesized antibody—are isolated through mechanical and chemical extraction methods.

The crude extract undergoes affinity chromatography or related purification techniques to isolate the antibody. Yield and purity are quantified via enzyme-linked immunosorbent assay (ELISA) and electrophoretic analysis (e.g., SDS-PAGE).

Rigorous quality assurance protocols, including functional and biochemical assays, are implemented to confirm the antibody's structural integrity, specificity, and suitability for downstream applications.

Producible Antibody Types

Our plant-based antibody production system is highly versatile and can be adapted to various antibody formats, including:

• Monoclonal antibodies
• Polyclonal antibodies
• Antibody fragments

Attractive Advantages

• Rapid Turnaround: Significantly faster production times compared to traditional mammalian cell culture.
• High Yields: Optimized expression systems for high-level antibody production.
• Cost-Effective: Lower production costs compared to conventional methods.
• Scalability: Easily scalable production to meet increasing demand.
• Reduced Risk: Minimal risk of contamination by human pathogens.
• Customizable Glycosylation: Ability to engineer glycosylation profiles for enhanced antibody function.

Published Data

Summary: Plant-based systems, particularly Nicotiana benthamiana, are being explored for the production of anti-HIV broadly neutralizing antibodies (bNAbs), due to their potential for cost-effectiveness and scalability.

Method: This study successfully expressed and characterized the targeted bNAb variants in glycoengineered N. benthamiana plants, and through in planta co-expression of tyrosyl protein sulfotransferase 1, introduced the crucial O-sulfated tyrosine modification in the antibody's CDR H3 loop.

Result: The resulting plant-produced bNAbs demonstrated similar structural and functional features, including potent neutralizing activity against subtype C viruses, compared to those produced in mammalian cells, highlighting the potential of plant-based systems for producing fully active bNAbs for HIV prevention and treatment.

Fig.2 SDS-PAGE analysis.2,3

Fig.3 Structural analysis.2,3

FAQs

At Creative Biolabs, our unwavering commitment is to empower your research and development with superior antibody production services. We achieve this by leveraging cutting-edge plant-based expression systems, ensuring the swift delivery of high-quality antibodies while maintaining cost-effectiveness. Our expertise and streamlined processes are dedicated to providing you with reliable and efficient solutions tailored to your specific antibody needs. If you are interested in using plant systems to quickly obtain high-quality antibody products, please contact us for further discussion.

References

1. Kumar, Manu, et al. "A Comprehensive overview on the production of vaccines in plant-based expression systems and the scope of plant biotechnology to combat against SARS-CoV-2 virus pandemics." Plants 10.6 (2021): 1213.
2. Singh A A, Pooe O, Kwezi L, et al. Plant-based production of highly potent anti-HIV antibodies with engineered posttranslational modifications[J]. Scientific reports, 2020, 10(1): 6201.
3. Distributed under Open Access License CC BY 4.0, without modification.